The heterogeneous expression of estrogen and the estrogen receptor (ER) alters depending on tumor stage and subcellular location and even changes with different prognoses in HGSOC patients [7,129,130]; however, hormones such as FSH, luteinizing hormone (LH), androgens, and their respective receptors are associated with disrupted cell proliferation and serous EOC development [129,130,131,132,133]. Here, BRD2 is linked to neoplasm.